Any current/future new fundraising through debt or equity?

The company is considering funding its CapEx through a combination of internal accruals, term loans (debt), and possibly fresh equity fundraising. The exact mix of equity and debt fundraising is still under discussion and is described as being in a fluid stage. Management will announce the fundraising plans once they are finalized and appropriate resolutions are passed. Current debt primarily comprises working capital, with no long-term debt outstanding. Future fundraising decisions will be made based on need, market conditions, and internal assessments.

Any current/future capex/capital investment/strategic investment?

Ongoing CapEx for expanding MCC capacity by 12,000 metric tons at Dahej H2 with a cost of around INR 106 crores. CapEx for CCS project totaling around INR 90 crores, expected to commercialize by Q1 FY28. Dahej has 20 acres of land and Kurnool has 25 acres available for future capacity expansions. Plans to gradually increase capacities based on market demand, targeting 50,000-70,000 metric tons in the coming years. Funding for CapEx will be a combination of internal accruals, term loans, and possible equity fundraising; plans are under discussion. No finalized fund-raising structure announced y

Future growth expectations in sales/revenue/volumes?

Sigachi expects revenue for FY27 in the range of INR 650-675 crores, supported by incremental capacities from Dahej and Jhagadia and an improved product mix. Expansion includes 12,000 metric tons capacity increase at Dahej H2 with CapEx of INR 106 crores, plus new CCS capacity (~INR 90 crores CapEx) expected to commercialize by Q1 FY28. Full capacity including MCC and CCS is expected to boost revenues significantly beyond FY27; the company targets INR 1000 crores turnover by around FY29. Volume growth expected from capacity expansion (from current 18,000 metric tons plus an additional 12

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 revenue guidance: INR 650-675 crores with EBITDA margin of 18-20%, improved from current margins (~7%) Utilization and margins expected to normalize by FY27 to mid-FY28, with margins reaching 15-20% range MCC utilization currently ~75-80%, expected to increase to 90-95% progressively post-accident safety stabilization Incremental capacity of 12,000 MT (Dahej H2) expected by end-FY27, contributing significant revenue and EBITDA growth API segment expected to grow from INR 60 crores currently to over INR 100 crores next year CCS product commercialization targeted by Q1 FY28, with

Current/ Expected Orderbook/ Pending Orders?

The company mentioned ongoing business talks and some clients already lined up supporting revenue growth. Expected revenue from the new 12,000 metric tons capacity expansion is around INR 200-220 crores. From the Contract Custom Synthesis (CCS) segment, approximately INR 100 crores of revenue is anticipated. Demand for CCS is good, with inquiries and customers requesting dispatches alongside MCC, indicating a healthy order pipeline. Current focus is on gradually increasing MCC utilization from 75-80% to 90-95% during the year. Overall, Sigachi expects to achieve a top-line of INR 650-675 crore

IN US

Sale is live|00:00:00left today

Sigachi Industries LtdQ1 FY26Pharmaceuticals & Biotechnology

Sigachi Industries Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹25.5P/E: 19.3Market Cap: ₹774 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Sigachi expects revenue for FY27 in the range of INR 650-675 crores, supported by incremental capacities from Dahej and Jhagadia and an improved product mix.
→Expansion includes 12,000 metric tons capacity increase at Dahej H2 with CapEx of INR 106 crores, plus new CCS capacity (~INR 90 crores CapEx) expected to commercialize by Q1 FY28.
→Full capacity including MCC and CCS is expected to boost revenues significantly beyond FY27; the company targets INR 1000 crores turnover by around FY29.
→Volume growth expected from capacity expansion (from current 18,000 metric tons plus an additional 12,000 metric tons).
→API segment revenue is projected to increase from 14% to about 18-20% of total revenue, adding to topline growth.
→Utilization rates for MCC are anticipated to increase from current 75-80% to north of 90% in FY27, enhancing output.
→New CCS product commands higher margins and pricing, expected to contribute meaningfully post-launch.

Margin guidance

Category 1

→FY27 revenue guidance: INR 650-675 crores with EBITDA margin of 18-20%, improved from current margins (~7%)
→Utilization and margins expected to normalize by FY27 to mid-FY28, with margins reaching 15-20% range
→MCC utilization currently ~75-80%, expected to increase to 90-95% progressively post-accident safety stabilization
→Incremental capacity of 12,000 MT (Dahej H2) expected by end-FY27, contributing significant revenue and EBITDA growth
→API segment expected to grow from INR 60 crores currently to over INR 100 crores next year
→CCS product commercialization targeted by Q1 FY28, with margins higher than 20% (CCS priced 2-3x MCC)
→Long-term revenue target of INR 1000 crores expected around FY29 (not by FY28)
→Management expects gradual debt reduction and return to higher profitability supported by expanded capacities and improved product mix

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company is considering funding its CapEx through a combination of internal accruals, term loans (debt), and possibly fresh equity fundraising.
→The exact mix of equity and debt fundraising is still under discussion and is described as being in a fluid stage.
→Management will announce the fundraising plans once they are finalized and appropriate resolutions are passed.
→Current debt primarily comprises working capital, with no long-term debt outstanding.
→Future fundraising decisions will be made based on need, market conditions, and internal assessments.

Order book

→The company mentioned ongoing business talks and some clients already lined up supporting revenue growth.
→Expected revenue from the new 12,000 metric tons capacity expansion is around INR 200-220 crores.
→From the Contract Custom Synthesis (CCS) segment, approximately INR 100 crores of revenue is anticipated.
→Demand for CCS is good, with inquiries and customers requesting dispatches alongside MCC, indicating a healthy order pipeline.
→Current focus is on gradually increasing MCC utilization from 75-80% to 90-95% during the year.
→Overall, Sigachi expects to achieve a top-line of INR 650-675 crores for FY27 supported by expanded capacities, API growth, and new business from CCS.
→The management indicated expansion plans are ongoing as long as market demand persists, with decisions on future CapEx and orderbook updates forthcoming.

Capex plans

Yes

→Ongoing CapEx for expanding MCC capacity by 12,000 metric tons at Dahej H2 with a cost of around INR 106 crores.
→CapEx for CCS project totaling around INR 90 crores, expected to commercialize by Q1 FY28.
→Dahej has 20 acres of land and Kurnool has 25 acres available for future capacity expansions.
→Plans to gradually increase capacities based on market demand, targeting 50,000-70,000 metric tons in the coming years.
→Funding for CapEx will be a combination of internal accruals, term loans, and possible equity fundraising; plans are under discussion.
→No finalized fund-raising structure announced yet, details to be disclosed in due course.

How does Sigachi Industries Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sigachi Industries Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sigachi Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio